Where can I find 326030.KS's financial statements?

SK Biopharmaceuticals Co., Ltd. (326030.KS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 326030.KS?

SK Biopharmaceuticals Co., Ltd. (326030.KS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 326030.KS update its statements?

SK Biopharmaceuticals Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

326030.KS

SK Biopharmaceuticals Co., Ltd.

KSC·Biotechnology · Healthcare

₩79,400₩2,600+3.39%

Market cap₩6.22T·Market closed·Jul 23 5:47 AM UTC

KRW · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	₩418.64B+1,510.2%	₩246.18B−41.2%	₩354.89B+44.2%	₩547.60B+54.3%	₩706.74B+29.1%
Cost of revenue	₩22.34B+1,031.5%	₩37.77B+69.1%	₩34.08B−9.8%	₩43.10B+26.5%	₩55.07B+27.8%
Gross profit	₩396.31B+1,549.6%	₩208.41B−47.4%	₩320.81B+53.9%	₩504.50B+57.3%	₩651.67B+29.2%
Research & development	₩114.53B+5.6%	₩122.82B+7.2%	₩137.70B+12.1%	₩161.31B+17.1%	₩174.34B+8.1%
General & administrative	₩49.96B−7.0%	₩62.44B+25.0%	₩61.73B−1.1%	₩63.86B+3.5%	₩80.62B+26.3%
Selling & marketing	₩39.84B+57.1%	₩49.89B+25.2%	₩40.14B−19.5%	₩50.93B+26.9%	₩65.67B+28.9%
SG&A (combined)	₩89.80B+13.5%	₩112.32B+25.1%	₩204.31B+81.9%	₩114.79B−43.8%	₩146.29B+27.4%
Other operating expenses	₩97.02B+27.7%	₩104.35B+7.6%	₩16.32B−84.4%	₩132.06B+709.2%	₩127.10B−3.8%
Total operating expenses	₩301.35B+14.4%	₩339.49B+12.7%	₩358.33B+5.6%	₩408.16B+13.9%	₩447.73B+9.7%
Operating income	₩94.96B+139.6%	−₩131.08B−238.0%	−₩20.63B+84.3%	₩96.34B+567.0%	₩203.94B+111.7%
Interest income	₩2.34B+10.5%	₩6.75B+188.3%	₩9.32B+37.9%	₩10.15B+8.9%	₩7.08B−30.2%
Interest expense	₩946.98M−78.8%	₩3.72B+292.5%	₩8.28B+122.8%	₩10.68B+29.0%	₩7.69B−28.0%
Other income / (expense), net	−₩23.68B−5,668.9%	−₩11.39B+51.9%	−₩23.23B−103.9%	−₩23.74B−2.2%	−₩53.05B−123.4%
Income before tax	₩71.28B+129.7%	−₩142.47B−299.9%	−₩43.86B+69.2%	₩72.60B+265.5%	₩150.88B+107.8%
Income tax expense	₩6.43B−14.3%	−₩3.04B−147.2%	−₩8.48B−179.1%	−₩154.38B−1,720.9%	−₩102.37B+33.7%
Net income	₩64.85B+126.2%	−₩139.43B−315.0%	−₩32.88B+76.4%	₩240.74B+832.1%	₩266.95B+10.9%

EPS (basic)	₩828.03+124.0%	−₩1,780.43−315.0%	−₩419.89+76.4%	₩3,066.97+830.4%	₩3,408.75+11.1%
EPS (diluted)	₩828.03+124.0%	−₩1,780.43−315.0%	−₩419.89+76.4%	₩3,066.97+830.4%	₩3,408.75+11.1%
Weighted avg shares (basic)	78,313,000	78,313,000	78,313,000	78,313,000	78,313,000
Weighted avg shares (diluted)	78,313,000	78,313,000	78,313,000	78,313,000	78,313,000

Depreciation & amortization	₩11.64B+7.2%	₩12.98B+11.5%	₩15.32B+18.0%	₩17.43B+13.8%	₩16.95B−2.8%
EBITDA	₩167.68B+174.7%	−₩125.77B−175.0%	−₩8.73B+93.1%	₩100.71B+1,254.1%	₩220.89B+119.3%

Frequently Asked Questions About 326030.KS

Where can I find 326030.KS's financial statements?: SK Biopharmaceuticals Co., Ltd. (326030.KS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 326030.KS?: SK Biopharmaceuticals Co., Ltd. (326030.KS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 326030.KS update its statements?: SK Biopharmaceuticals Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

₩418.64B+1,510.2%

₩246.18B−41.2%

₩354.89B+44.2%

₩547.60B+54.3%

₩706.74B+29.1%

Cost of revenue

₩22.34B+1,031.5%

₩37.77B+69.1%

₩34.08B−9.8%

₩43.10B+26.5%

₩55.07B+27.8%

Gross profit

₩396.31B+1,549.6%

₩208.41B−47.4%

₩320.81B+53.9%

₩504.50B+57.3%

₩651.67B+29.2%

Research & development

₩114.53B+5.6%

₩122.82B+7.2%

₩137.70B+12.1%

₩161.31B+17.1%

₩174.34B+8.1%

General & administrative

₩49.96B−7.0%

₩62.44B+25.0%

₩61.73B−1.1%

₩63.86B+3.5%

₩80.62B+26.3%

Selling & marketing

₩39.84B+57.1%

₩49.89B+25.2%

₩40.14B−19.5%

₩50.93B+26.9%

₩65.67B+28.9%

SG&A (combined)

₩89.80B+13.5%

₩112.32B+25.1%

₩204.31B+81.9%

₩114.79B−43.8%

₩146.29B+27.4%

Other operating expenses

₩97.02B+27.7%

₩104.35B+7.6%

₩16.32B−84.4%

₩132.06B+709.2%

₩127.10B−3.8%

Total operating expenses

₩301.35B+14.4%

₩339.49B+12.7%

₩358.33B+5.6%

₩408.16B+13.9%

₩447.73B+9.7%

Operating income

₩94.96B+139.6%

−₩131.08B−238.0%

−₩20.63B+84.3%

₩96.34B+567.0%

₩203.94B+111.7%

Interest income

₩2.34B+10.5%

₩6.75B+188.3%

₩9.32B+37.9%

₩10.15B+8.9%

₩7.08B−30.2%

Interest expense

₩946.98M−78.8%

₩3.72B+292.5%

₩8.28B+122.8%

₩10.68B+29.0%

₩7.69B−28.0%

Other income / (expense), net

−₩23.68B−5,668.9%

−₩11.39B+51.9%

−₩23.23B−103.9%

−₩23.74B−2.2%

−₩53.05B−123.4%

Income before tax

₩71.28B+129.7%

−₩142.47B−299.9%

−₩43.86B+69.2%

₩72.60B+265.5%

₩150.88B+107.8%

Income tax expense

₩6.43B−14.3%

−₩3.04B−147.2%

−₩8.48B−179.1%

−₩154.38B−1,720.9%

−₩102.37B+33.7%

Net income

₩64.85B+126.2%

−₩139.43B−315.0%

−₩32.88B+76.4%

₩240.74B+832.1%

₩266.95B+10.9%

EPS (basic)

₩828.03+124.0%

−₩1,780.43−315.0%

−₩419.89+76.4%

₩3,066.97+830.4%

₩3,408.75+11.1%

EPS (diluted)

₩828.03+124.0%

−₩1,780.43−315.0%

−₩419.89+76.4%

₩3,066.97+830.4%

₩3,408.75+11.1%

Weighted avg shares (basic)

78,313,000

Weighted avg shares (diluted)

78,313,000

Depreciation & amortization

₩11.64B+7.2%

₩12.98B+11.5%

₩15.32B+18.0%

₩17.43B+13.8%

₩16.95B−2.8%

EBITDA

₩167.68B+174.7%

−₩125.77B−175.0%

−₩8.73B+93.1%

₩100.71B+1,254.1%

₩220.89B+119.3%